Search
Pyridostigmine
go.drugbank.com/drugs/DB00545ApprovedInvestigationalBy inhibiting the breakdown of acetylcholine in the neuromuscular junction, they increase signalling and relieve symptoms. … [L32408, L32413] In addition to treating myasthenia gravis, pyridostigmine is used to reverse neuromuscular blocks, relieve symptoms in congenital myasthenic syndromes, and protect against certain nerve
Products: BRIGADAN-TCyclosporine
go.drugbank.com/drugs/DB00091ApprovedInvestigationalVet approved[A174049] Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Secretin human
go.drugbank.com/drugs/DB09532ApprovedInvestigationalThe main action of secretin is to stimulate the pancreas to secrete pancreatic juice for pH regulation in the small intestines. … The hormone is produced from the enterochromaffin cells in the duodenum in response to the duodenal content with the pH less than 4.5 [L1875].
Cetalkonium
go.drugbank.com/drugs/DB11583ApprovedWithdrawnCetalkonium is a C16 alkyl benzalkonium chloride derivative with an amphipathic property which allows it to be used in different types of formulations. … [L2137] Cetalkonium is approved by the FDA for its use in over-the-counter products as a skin protectant.[L2737] By Health Canada, it is also approved for its use in over-the-counter products.[L1113]
Pembrolizumab
go.drugbank.com/drugs/DB09037ApprovedInvestigational[F136] It was developed by Merck & Co and first approved for the treatment of metastatic malignant melanoma by the FDA on September 4, 2014,[L2954] becoming the first approved therapy against PD-1. … [L38934,L43257] In September 2025, the US FDA approved a formulation of pembrolizumab that includes [berahyaluronidase alfa] (Keytruda QLEX) to allow for subcutaneous administration.[L54026]
Tesamorelin
go.drugbank.com/drugs/DB08869ApprovedInvestigationalLipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and hyperlipidemia associated with antiretroviral therapy for HIV infection.
Levacetylmethadol
go.drugbank.com/drugs/DB01227ApprovedWithdrawnLevacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well.[L44052,T862]
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromePralsetinib
go.drugbank.com/drugs/DB15822ApprovedInvestigationalIt is currently marketed under the brand name GAVRETO™ by Blueprint Medicines.[L15986] … Pralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.
Enfuvirtide
go.drugbank.com/drugs/DB00109ApprovedInvestigationalEnfuvirtide is a 36 amino acid biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake … The first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide works by inhibiting HIV-1 fusion with CD4 cells.
Linerixibat
go.drugbank.com/drugs/DB11729ApprovedInvestigationalto be the primary pruritogens. … [L56127] PBC is a rare, chronic autoimmune liver disease characterized by the destruction of small bile ducts, leading to cholestasis and the systemic accumulation of bile acids, which are hypothesized